| Michael A. Mcaleese, Od, Pa | |
|
2380 U.s. Hwy 9 South, C-6, Howell, NJ 07731 | |
| (732) 984-6930 | |
| (732) 414-1061 |
| Full Name | Michael A. Mcaleese, Od, Pa |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 2380 U.s. Hwy 9 South, C-6, Howell, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306033436 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4888 (New Jersey) | Primary |
| Provider Name | Michael A Mcaleese |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1720156177 PECOS PAC ID: 0840254884 Enrollment ID: I20041119000081 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Provider Name | Colleen M Schubel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1164404570 PECOS PAC ID: 0749218949 Enrollment ID: I20050729000102 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Provider Name | Robert B Johnston |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528150281 PECOS PAC ID: 3971686429 Enrollment ID: I20080207000337 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Provider Name | Lynn Zhang |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790032647 PECOS PAC ID: 4688829724 Enrollment ID: I20130221000294 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Provider Name | Monica F Ghabour |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1952972770 PECOS PAC ID: 9830592369 Enrollment ID: I20210721003378 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Provider Name | Francesca Benedetta Musto |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1548994460 PECOS PAC ID: 7618351198 Enrollment ID: I20220901000786 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael A. Mcaleese, Od, Pa 2380 U.s. Hwy 9 South, C-6, Howell, NJ 07731 Ph: (732) 984-6930 | Michael A. Mcaleese, Od, Pa 2380 U.s. Hwy 9 South, C-6, Howell, NJ 07731 Ph: (732) 984-6930 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.
Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.
Patients with dementia are hospitalized at higher rates and involved in transitional care more frequently than those who are cognitively unimpaired.
IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society.
› Verified 6 days ago
Drs. Matzo And Rosenheck, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 2220 Us Highway 9, Howell, NJ 07731 Phone: 732-780-0088 | |
The Eye Doctor Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4900 Route 9 S, Howell, NJ 07731 Phone: 732-275-8400 | |
Archana S Patel, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6951 Us Highway 9 Ste 1, Howell, NJ 07731 Phone: 732-994-0442 | |
Dr. Jamie D. Costello, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 53 Kent Rd, Costello Eye Care, Howell, NJ 07731 Phone: 732-534-5622 | |
Dr. Mohit Kapoor, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4900 Us Highway 9, Howell, NJ 07731 Phone: 973-617-7421 | |
Eyes On 9 Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6951 Route 9, Howell, NJ 07731 Phone: 347-392-2673 |